These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 32245699)

  • 41. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
    Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
    J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
    [No Abstract]   [Full Text] [Related]  

  • 46. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
    Stordal B; Timms K; Farrelly A; Gallagher D; Busschots S; Renaud M; Thery J; Williams D; Potter J; Tran T; Korpanty G; Cremona M; Carey M; Li J; Li Y; Aslan O; O'Leary JJ; Mills GB; Hennessy BT
    Mol Oncol; 2013 Jun; 7(3):567-79. PubMed ID: 23415752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
    Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
    Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    Davies H; Glodzik D; Morganella S; Yates LR; Staaf J; Zou X; Ramakrishna M; Martin S; Boyault S; Sieuwerts AM; Simpson PT; King TA; Raine K; Eyfjord JE; Kong G; Borg Å; Birney E; Stunnenberg HG; van de Vijver MJ; Børresen-Dale AL; Martens JW; Span PN; Lakhani SR; Vincent-Salomon A; Sotiriou C; Tutt A; Thompson AM; Van Laere S; Richardson AL; Viari A; Campbell PJ; Stratton MR; Nik-Zainal S
    Nat Med; 2017 Apr; 23(4):517-525. PubMed ID: 28288110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
    Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
    Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
    Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
    Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.